Bluejay Diagnostics Inc (BJDX) Quote

BJDX MONSTER PLAY AND NOBODY SAW IT

$9 + 132% cash some out

On December 3, 2024, Bluejay Diagnostics, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market notifying the Company that, based on the closing bid price of the Company’s common stock having been at least $1.00 per share for the required period, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and the minimum bid price deficiency matter previously disclosed by the Company on March 4, 2024 is now closed.

Another 500k floater $5,72 + 46%

BJDX...THTA 6.25 LOOKS RIGHT

BJDX SHES OFF AND RUNNING

BJDX SECOND RS CAN BE GOOD ONES

BJDX.........................https://stockcharts.com/h-sc/ui?s=BJDX&p=W&b=5&g=0&id=p86431144783

BJDX MICRO NASY POS PLAY..SCALP IT

insane volume.

Nice pump before reverse split 

BJDX.........................https://stockcharts.com/h-sc/ui?s=BJDX&p=W&b=5&g=0&id=p86431144783

Proposal 1. Approval and adoption of an amendment to the Company’s amended and restated certificate of incorporation, as amended, to effect a reverse stock split of the Company’s common stock - The Company’s stockholders approved and adopted an amendment to the Company’s certificate of incorporation to effect a reverse stock split of all of the Company’s outstanding shares of common stock by one of several fixed ratios between 1-for-20 and 1-for-50 (the “Reverse Stock Split”). The voting results for the proposal were as follows:

In with a starter, will be buying .07s if they become available

Reverse split to be voted and approved Oct 23 1pm

Great Vol. Today !!

Seems ready

Anytime ready

Okay thanks

Yup, r/s coming soon - Pre 14A dropped Friday

Super rebound next week?

.18 dip

.19 dip

August 28, 2024, Nasdaq’s Listing Qualifications Staff notified the Company that it has extended the time period for the Company to regain compliance with the Minimum Bid Requirement until February 24, 2025. To regain compliance, the closing bid price of the Common Stock must be at least $1.00 or higher for a minimum of ten consecutive business days.

The Company intends to continue to actively monitor the closing bid price of the Common Stock and will evaluate available options to regain compliance with the Minimum Bid Requirement. Specifically, the Company has confirmed to Nasdaq that, if necessary, it will implement a reverse stock split of its outstanding common stock (if approved by the Company’s stockholders) to attempt to regain compliance. If the Company does not regain compliance within the additional compliance period, Nasdaq will provide notice that the Common Stock will be subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel. There can be no assurance that the Company will regain compliance with the Minimum Bid Requirement during the 180-day additional compliance period or maintain compliance with the other Nasdaq listing requirements.

3.6m shares traded whole float interesting

Hedgies loading down here News must be around the corner. Unusual volume

Pounded down by hedgies no mercy .. . Last offering at $1.63 long ways up..
The purchase price of each Common Unit is $1.63, and the purchase price of each Prefunded Unit is $1.6299 (which is equal to the public offering price per Common Unit minus $0.0001). The Prefunded Warrants will be immediately exercisable and may be exercised at any time until all the Prefunded Warrants are exercised in full.
The Class C Warrants, which will not be exercisable until approval by the Company’s stockholders, will have an initial exercise price of $1.96 per share, and will expire five (5) years from the date of such stockholder approval. Each Class D Warrant will be exercisable immediately. The exercise price and number of shares of Common Stock issuable under the Class D Warrants are subject to adjustment as described in the Class D Warrant. The Company intends to use the net proceeds from the offering to (i) repay $2.3 million in outstanding debt that will be due and payable upon consummation of the offering and (ii) fund matters related to obtaining FDA approval (including clinical studies related thereto), as well as for other research and development activities, and for general working capital needs.

Bottom feeder at .20-.22 let’s go some still relatively low floater

Any possible catalyst?

This stock sucks!!!

Looks like bottom is found

C'mon Drop that SYMON - II study for Sepsis

BJDX new 52=week low

Chance for an r/s anytime soon here?

BJDX..............................https://stockcharts.com/h-sc/ui?s=BJDX&p=W&b=5&g=0&id=p86431144783

Brewing

BJDX new 52 week low

BJDX looks like it wants to make a move here.

BJDX new 52 week low

This looks like a double bottom pattern at .53

Recovering soon?

BJDX new 52 week low

BJDX new 52 week low

BJDX new 52 week low

BJDX new 52 week low

I am surprised they were able to make it move with this PR.

That was quick

SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients

Whoops, I did it, again

BJDX.................................https://stockcharts.com/h-sc/ui?s=BJDX&p=W&b=5&g=0&id=p86431144783

Yes......Sad but true.....
I wish the SEC would change the rules, about doing a RS......Make it really hard to get permission......
Sorry.....Your only other choices are to create more shares, de=list, or die.....
JMO